{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T22:02:42Z","timestamp":1792360962573,"version":"4.4.0"},"reference-count":82,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2022,6,4]],"date-time":"2022-06-04T00:00:00Z","timestamp":1654300800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Radiation therapy plays a central role in the treatment of pancreatic cancer. While generally shown to be feasible, proton irradiation, particularly when an ablative dose is planned, remains a challenge, especially due to tumor motion and the proximity to organs at risk, like the stomach, duodenum, and bowel. Clinically, standard doses of proton radiation treatment have not been shown to be statistically different from photon radiation treatment in terms of oncologic outcomes and toxicity rates as per non-randomized comparative studies. Fractionation schedules and concurrent chemotherapy combinations are yet to be optimized for proton therapy and are the subject of ongoing trials.<\/jats:p>","DOI":"10.3390\/cancers14112789","type":"journal-article","created":{"date-parts":[[2022,6,4]],"date-time":"2022-06-04T09:42:32Z","timestamp":1654335752000},"page":"2789","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Proton Therapy in the Management of Pancreatic Cancer"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0266-8376","authenticated-orcid":false,"given":"Jana M.","family":"Kobeissi","sequence":"first","affiliation":[{"name":"Department of Radiation Oncology, School of Medicine, American University of Beirut Medical Center, Beirut 1107, Lebanon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0867-3694","authenticated-orcid":false,"suffix":"II","given":"Charles B.","family":"Simone","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, New York Proton Center, New York, NY 10035, USA"},{"name":"Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY 10027, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haibo","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, New York Proton Center, New York, NY 10035, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4508-2391","authenticated-orcid":false,"given":"Lara","family":"Hilal","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, School of Medicine, American University of Beirut Medical Center, Beirut 1107, Lebanon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla","family":"Hajj","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, New York Proton Center, New York, NY 10035, USA"},{"name":"Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY 10027, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,6,4]]},"reference":[{"key":"ref_1","unstructured":"National Cancer Institute (2022, April 29). SEER Cancer Stat Facts: Pancreatic Cancer, Available online: https:\/\/seer.cancer.gov\/statfacts\/html\/pancreas.html."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/s41572-019-0064-5","article-title":"Author Correction: Radiotherapy toxicity","volume":"5","author":"Niedermann","year":"2019","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.addr.2016.11.006","article-title":"Proton therapy\u2014Present and future","volume":"109","author":"Mohan","year":"2017","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_4","unstructured":"(2022, April 29). National Comprehensive Cancer Network. Pancreatic Adenocarcinoma. Available online: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/pancreatic.pdf."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1038\/s41416-020-0980-x","article-title":"Considerations for the treatment of pancreatic cancer during the COVID-19 pandemic: The UK consensus position","volume":"123","author":"Jones","year":"2020","journal-title":"Br. J. Cancer"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"S97","DOI":"10.1016\/j.ijrobp.2018.06.250","article-title":"Estimation of the Alpha-beta Ratio for Chemoradiation of Locally Advanced Pancreatic Cancer","volume":"102","author":"Prior","year":"2018","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"775597","DOI":"10.3389\/fonc.2021.775597","article-title":"Charged Particle Irradiation for Pancreatic Cancer: A Systematic Review of In Vitro Studies","volume":"11","author":"Wang","year":"2022","journal-title":"Front. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1016\/S1470-2045(21)00347-8","article-title":"Pan-cancer prediction of radiotherapy benefit using genomic-adjusted radiation dose (GARD): A cohort-based pooled analysis","volume":"22","author":"Scott","year":"2021","journal-title":"Lancet Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1200\/JCO.21.02233","article-title":"Neoadjuvant Chemoradiotherapy Versus Upfront Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Long-Term Results of the Dutch Randomized PREOPANC Trial","volume":"40","author":"Versteijne","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1056\/NEJMoa1809775","article-title":"FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer","volume":"379","author":"Conroy","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1097\/00000658-199912000-00006","article-title":"Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: Phase III trial of the EORTC gastrointestinal tract cancer cooperative group","volume":"230","author":"Klinkenbijl","year":"1999","journal-title":"Ann. Surg."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1056\/NEJMoa032295","article-title":"A Randomized Trial of Chemoradiotherapy and Chemotherapy after Resection of Pancreatic Cancer","volume":"350","author":"Neoptolemos","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1001\/jamaoncol.2021.0057","article-title":"Association of Ablative Radiation Therapy with Survival among Patients with Inoperable Pancreatic Cancer","volume":"7","author":"Reyngold","year":"2021","journal-title":"JAMA Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"166","DOI":"10.21037\/jgo.2019.03.02","article-title":"Proton beam radiotherapy for pancreas cancer","volume":"11","author":"Rutenberg","year":"2020","journal-title":"J. Gastrointest. Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"644","DOI":"10.21037\/jgo.2016.05.06","article-title":"Clinical outcomes and toxicities of proton radiotherapy for gastrointestinal neoplasms: A systematic review","volume":"7","author":"Verma","year":"2016","journal-title":"J. Gastrointest. Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"05RM01","DOI":"10.1088\/1361-6560\/abcd16","article-title":"Roadmap: Proton therapy physics and biology","volume":"66","author":"Paganetti","year":"2021","journal-title":"Phys. Med. Biol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/S0360-3016(00)00522-8","article-title":"The role of proton therapy in the treatment of large irradiation volumes: A comparative planning study of pancreatic and biliary tumors","volume":"48","author":"Zurlo","year":"2000","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S0958-3947(01)00072-3","article-title":"Comparative treatment planning between proton and x-ray therapy in pancreatic cancer","volume":"26","author":"McDonough","year":"2001","journal-title":"Med. Dosim."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.radonc.2009.04.015","article-title":"Dose escalation with proton or photon radiation treatment for pancreatic cancer","volume":"92","author":"Bouchard","year":"2009","journal-title":"Radiother. Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1016\/j.ijrobp.2007.02.056","article-title":"Dosimetric Feasibility of Hypofractionated Proton Radiotherapy for Neoadjuvant Pancreatic Cancer Treatment","volume":"68","author":"Kozak","year":"2007","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_21","first-page":"374","article-title":"Proton therapy may allow for comprehensive elective nodal coverage for patients receiving neoadjuvant radiotherapy for localized pancreatic head cancers","volume":"4","author":"Lee","year":"2013","journal-title":"J. Gastrointest. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.ijrobp.2011.05.045","article-title":"Protons Offer Reduced Normal-Tissue Exposure for Patients Receiving Postoperative Radiotherapy for Resected Pancreatic Head Cancer","volume":"83","author":"Nichols","year":"2012","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.meddos.2013.11.005","article-title":"A comprehensive dosimetric study of pancreatic cancer treatment using three-dimensional conformal radiation therapy (3DCRT), intensity-modulated radiation therapy (IMRT), volumetric-modulated radiation therapy (VMAT), and passive-scattering and modulated-scanning proton therapy (PT)","volume":"39","author":"Ding","year":"2014","journal-title":"Med. Dosim."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"702","DOI":"10.14338\/IJPT-14-00008.1","article-title":"Protons Offer Reduced Tissue Exposure for Patients Receiving Radiation Therapy for Pancreatic Cancer","volume":"1","author":"Slater","year":"2014","journal-title":"Int. J. Part. Ther."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"081711","DOI":"10.1118\/1.4887797","article-title":"A dosimetric comparison of proton and photon therapy in unresectable cancers of the head of pancreas","volume":"41","author":"Thompson","year":"2014","journal-title":"Med. Phys."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1186\/s13014-018-1165-0","article-title":"Comparison of different treatment planning approaches for intensity-modulated proton therapy with simultaneous integrated boost for pancreatic cancer","volume":"13","author":"Stefanowicz","year":"2018","journal-title":"Radiat. Oncol."},{"key":"ref_27","first-page":"24","article-title":"Dose-escalated simultaneously integrated boost photon or proton therapy in pancreatic cancer in an in-silico study: Gastrointestinal organs remain critical","volume":"27","author":"Stefanowicz","year":"2021","journal-title":"Clin. Transl. Radiat. Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1186\/s13014-020-01592-6","article-title":"Radiobiological model-based approach to determine the potential of dose-escalated robust intensity-modulated proton radiotherapy in reducing gastrointestinal toxicity in the treatment of locally advanced unresectable pancreatic cancer of the head","volume":"15","author":"Raturi","year":"2020","journal-title":"Radiat. Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"E172","DOI":"10.1016\/j.ijrobp.2015.07.990","article-title":"Is Pencil Beam Scanning Dosimetrically Advantageous Compared to Passively Scattered Proton Therapy for Unresectable Pancreatic Cancer?","volume":"93","author":"Chuong","year":"2015","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1002\/acm2.13429","article-title":"Dosimetric impact of simulated changes in large bowel content during proton therapy with simultaneous integrated boost for locally advanced pancreatic cancer","volume":"22","author":"Narita","year":"2021","journal-title":"J. Appl. Clin. Med. Phys."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"3051","DOI":"10.1088\/1361-6560\/aa6419","article-title":"Comparing the dosimetric impact of interfractional anatomical changes in photon, proton and carbon ion radiotherapy for pancreatic cancer patients","volume":"62","author":"Houweling","year":"2017","journal-title":"Phys. Med. Biol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"085011","DOI":"10.1088\/1361-6560\/ab1175","article-title":"Comparing the effectiveness and efficiency of various gating approaches for PBS proton therapy of pancreatic cancer using 4D-MRI datasets","volume":"64","author":"Dolde","year":"2019","journal-title":"Phys. Med. Biol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s13014-019-1231-2","article-title":"4DMRI-based investigation on the interplay effect for pencil beam scanning proton therapy of pancreatic cancer patients","volume":"14","author":"Dolde","year":"2019","journal-title":"Radiat. Oncol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"S185","DOI":"10.1016\/j.ijrobp.2013.06.477","article-title":"Scanning Beam Stereotactic Body Proton Therapy (SBPT) for Pancreatic Cancer: A Dosimetric Feasibility Study","volume":"87","author":"Sio","year":"2013","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.ejmp.2015.12.009","article-title":"Spot-scanned pancreatic stereotactic body proton therapy: A dosimetric feasibility and robustness study","volume":"32","author":"Sio","year":"2016","journal-title":"Phys. Med."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"747532","DOI":"10.3389\/fonc.2021.747532","article-title":"Investigate the Dosimetric and Potential Clinical Benefits Utilizing Stereotactic Body Radiation Therapy With Simultaneous Integrated Boost Technique for Locally Advanced Pancreatic Cancer: A Comparison Between Photon and Proton Beam Therapy","volume":"11","author":"Liu","year":"2021","journal-title":"Front. Oncol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"R99","DOI":"10.1088\/0031-9155\/57\/11\/R99","article-title":"Range uncertainties in proton therapy and the role of Monte Carlo simulations","volume":"57","author":"Paganetti","year":"2012","journal-title":"Phys. Med. Biol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"7056","DOI":"10.1088\/1361-6560\/aa7dc9","article-title":"Comprehensive analysis of proton range uncertainties related to stopping-power-ratio estimation using dual-energy CT imaging","volume":"62","author":"Li","year":"2017","journal-title":"Phys. Med. Biol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"4095","DOI":"10.1088\/0031-9155\/57\/13\/4095","article-title":"Comprehensive analysis of proton range uncertainties related to patient stopping-power-ratio estimation using the stoichiometric calibration","volume":"57","author":"Yang","year":"2012","journal-title":"Phys. Med. Biol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"100757","DOI":"10.1016\/j.adro.2021.100757","article-title":"A Beam-Specific Optimization Target Volume for Stereotactic Proton Pencil Beam Scanning Therapy for Locally Advanced Pancreatic Cancer","volume":"6","author":"Han","year":"2021","journal-title":"Adv. Radiat. Oncol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.radonc.2021.11.002","article-title":"Reduction of clinical safety margins in proton therapy enabled by the clinical implementation of dual-energy CT for direct stopping-power prediction","volume":"166","author":"Peters","year":"2022","journal-title":"Radiother. Oncol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"212","DOI":"10.21037\/jgo.2019.11.07","article-title":"Managing treatment-related uncertainties in proton beam radiotherapy for gastrointestinal cancers","volume":"11","author":"Tryggestad","year":"2020","journal-title":"J. Gastrointest. Oncol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1016\/j.ijrobp.2017.08.006","article-title":"A Novel Absorbable Radiopaque Hydrogel Spacer to Separate the Head of the Pancreas and Duodenum in Radiation Therapy for Pancreatic Cancer","volume":"99","author":"Rao","year":"2017","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"03NT02","DOI":"10.1088\/1361-6560\/ab66e1","article-title":"Validation of the proton range accuracy and optimization of CT calibration curves utilizing range probing","volume":"65","author":"Meijers","year":"2020","journal-title":"Phys. Med. Biol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"4020","DOI":"10.1002\/mp.13094","article-title":"4D robust optimization including uncertainties in time structures can reduce the interplay effect in proton pencil beam scanning radiation therapy","volume":"45","author":"Engwall","year":"2018","journal-title":"Med. Phys."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.ijrobp.2020.01.013","article-title":"Robust Optimization for Intensity Modulated Proton Therapy to Redistribute High Linear Energy Transfer from Nearby Critical Organs to Tumors in Head and Neck Cancer","volume":"107","author":"Liu","year":"2020","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"15675","DOI":"10.1200\/jco.2008.26.15_suppl.15675","article-title":"A phase I study of proton beam therapy for locally advanced pancreatic cancer: Analysis of feasibility and anti-tumor effect","volume":"26","author":"Kamigaki","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.ijrobp.2009.10.061","article-title":"Phase I Study of Preoperative Short-Course Chemoradiation with Proton Beam Therapy and Capecitabine for Resectable Pancreatic Ductal Adenocarcinoma of the Head","volume":"79","author":"Hong","year":"2011","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1016\/j.ijrobp.2014.03.034","article-title":"A Phase 1\/2 and Biomarker Study of Preoperative Short Course Chemoradiation with Proton Beam Therapy and Capecitabine Followed by Early Surgery for Resectable Pancreatic Ductal Adenocarcinoma","volume":"89","author":"Hong","year":"2014","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1007\/s13566-013-0114-7","article-title":"Dosimetric predictors of nausea and vomiting: An exploratory analysis of a prospective phase I\/II trial with neoadjuvant accelerated short-course radiotherapy and capecitabine for resectable pancreatic cancer","volume":"2","author":"Tseng","year":"2013","journal-title":"J. Radiat. Oncol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.radonc.2011.12.029","article-title":"A phase I\/II study of gemcitabine-concurrent proton radiotherapy for locally advanced pancreatic cancer without distant metastasis","volume":"103","author":"Terashima","year":"2012","journal-title":"Radiother. Oncol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1007\/s00535-013-0857-3","article-title":"Upper gastrointestinal complications associated with gemcitabine-concurrent proton radiotherapy for inoperable pancreatic cancer","volume":"49","author":"Takatori","year":"2013","journal-title":"J. Gastroenterol."},{"key":"ref_53","first-page":"E33","article-title":"RE: Takatori K, Terashima K, Yoshida R, Horai A, Satake S, Ose T, Kitajima N, Kinoshita Y, Demizu Y, Fuwa N. Upper gastrointestinal complications associated with gemcitabine-concurrent proton radiotherapy for inoperable pancreatic cancer. J Gastroenterol. 2013; (E-pub only)","volume":"4","author":"Nichols","year":"2013","journal-title":"J. Gastrointest. Oncol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"E153","DOI":"10.1016\/j.ijrobp.2017.06.966","article-title":"Image-Guided Hypofractionated Proton Therapy and Concurrent Chemotherapy for Inoperable Locally Advanced Pancreatic Cancer: Toxicities and Preliminary Outcomes","volume":"99","author":"Hattori","year":"2017","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s13014-020-01731-z","article-title":"Surgical spacer placement for proton radiotherapy in locally advanced pancreatic body and tail cancers: Initial clinical results","volume":"16","author":"Lee","year":"2021","journal-title":"Radiat. Oncol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s13014-022-02001-w","article-title":"Factors associated with long-term survival in gemcitabine-concurrent proton radiotherapy for non-metastatic locally advanced pancreatic cancer: A single-center retrospective study","volume":"17","author":"Ogura","year":"2022","journal-title":"Radiat. Oncol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"498","DOI":"10.3109\/0284186X.2012.762997","article-title":"Proton therapy with concomitant capecitabine for pancreatic and ampullary cancers is associated with a low incidence of gastrointestinal toxicity","volume":"52","author":"Nichols","year":"2013","journal-title":"Acta Oncol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"692","DOI":"10.14338\/IJPT.14-00006.1","article-title":"Proton Therapy and Concomitant Capecitabine for Non-Metastatic Unresectable Pancreatic Adenocarcinoma","volume":"1","author":"Sachsman","year":"2014","journal-title":"Int. J. Part. Ther."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.adro.2018.04.003","article-title":"Initial experience with intensity modulated proton therapy for intact, clinically localized pancreas cancer: Clinical implementation, dosimetric analysis, acute treatment-related adverse events, and patient-reported outcomes","volume":"3","author":"Jethwa","year":"2018","journal-title":"Adv. Radiat. Oncol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"103","DOI":"10.4240\/wjgs.v9.i4.103","article-title":"Feasibility of pancreatectomy following high-dose proton therapy for unresectable pancreatic cancer","volume":"9","author":"Hitchcock","year":"2017","journal-title":"World J. Gastrointest. Surg."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1001\/jamaoncol.2019.0892","article-title":"Total Neoadjuvant Therapy with FOLFIRINOX in Combination with Losartan Followed by Chemoradiotherapy for Locally Advanced Pancreatic Cancer: A Phase 2 Clinical Trial","volume":"5","author":"Murphy","year":"2019","journal-title":"JAMA Oncol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1200\/JCO.2018.36.4_suppl.513","article-title":"Postoperative proton therapy for pancreatic cancer patients enrolled on the Proton Collaborative Group (PCG) registry","volume":"36","author":"Nichols","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"2587","DOI":"10.1245\/s10434-019-07471-z","article-title":"Proton Radiotherapy for Isolated Local Recurrence of Primary Resected Pancreatic Ductal Adenocarcinoma","volume":"26","author":"Mizumoto","year":"2019","journal-title":"Ann. Surg. Oncol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"665","DOI":"10.21037\/jgo.2017.03.04","article-title":"Proton beam reirradiation for locally recurrent pancreatic adenocarcinoma","volume":"8","author":"Boimel","year":"2017","journal-title":"J. Gastrointest. Oncol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"E68","DOI":"10.1016\/j.ijrobp.2018.07.408","article-title":"Proton Beam Therapy for Inoperable Stage III Pancreatic Cancer","volume":"102","author":"Arimura","year":"2018","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.radonc.2019.03.012","article-title":"Concurrent chemoradiotherapy using proton beams for unresectable locally advanced pancreatic cancer","volume":"136","author":"Hiroshima","year":"2019","journal-title":"Radiother. Oncol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1533033818783879","DOI":"10.1177\/1533033818783879","article-title":"Effectiveness and Safety of Simultaneous Integrated Boost-Proton Beam Therapy for Localized Pancreatic Cancer","volume":"17","author":"Kim","year":"2018","journal-title":"Technol. Cancer Res. Treat."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"21712","DOI":"10.1038\/s41598-020-78875-1","article-title":"Efficacy and feasibility of proton beam radiotherapy using the simultaneous integrated boost technique for locally advanced pancreatic cancer","volume":"10","author":"Kim","year":"2020","journal-title":"Sci. Rep."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"S311","DOI":"10.1016\/j.ijrobp.2013.06.817","article-title":"Acute Toxicity of Proton Versus Photon Chemoradiation Therapy for Pancreatic Adenocarcinoma: A Cohort Study","volume":"87","author":"Lukens","year":"2013","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"E208","DOI":"10.1016\/j.ijrobp.2016.06.1114","article-title":"Acute Toxicity of Proton Versus Photon Adjuvant Chemoradiation in the Treatment of Pancreatic Cancer: A Cohort Study","volume":"96","author":"Woodhouse","year":"2016","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.pan.2017.07.191","article-title":"Comparison of proton beam radiotherapy and hyper-fractionated accelerated chemoradiotherapy for locally advanced pancreatic cancer","volume":"17","author":"Maemura","year":"2017","journal-title":"Pancreatology"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1186\/s13014-021-01969-1","article-title":"Vertebral body and splenic irradiation are associated with lymphopenia in localized pancreatic cancer treated with stereotactic body radiation therapy","volume":"16","author":"Reddy","year":"2021","journal-title":"Radiat. Oncol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1097\/COC.0b013e3182940ff9","article-title":"The Association Between Chemoradiation-related Lymphopenia and Clinical Outcomes in Patients with Locally Advanced Pancreatic Adenocarcinoma","volume":"38","author":"Wild","year":"2015","journal-title":"Am. J. Clin. Oncol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"23","DOI":"10.14338\/IJPT-17-00033.1","article-title":"Lymphocyte-Sparing Effect of Proton Therapy in Patients with Esophageal Cancer Treated with Definitive Chemoradiation","volume":"4","author":"Fang","year":"2018","journal-title":"Int. J. Part. Ther."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"57","DOI":"10.2147\/JHC.S282062","article-title":"Radiation-Associated Lymphopenia and Outcomes of Patients with Unresectable Hepatocellular Carcinoma Treated with Radiotherapy","volume":"8","author":"De","year":"2021","journal-title":"J. Hepatocell. Carcinoma"},{"key":"ref_76","unstructured":"Proton Collaborative Group, and University of Florida Health (2015). Proton Radiation for Unresectable, Borderline Resectable, or Medically Inoperable Carcinoma of the Pancreas, University of Florida Health."},{"key":"ref_77","unstructured":"Georgetown University (2021). Study of Proton Therapy in Adjuvant Pancreatic Cancer, Georgetown University."},{"key":"ref_78","unstructured":"Massachusetts General Hospital (2022). Short Course Radiation Therapy with Proton or Photon Beam Capecitabine and Hydroxychloroquine for Resectable Pancreatic Cancer, Massachusetts General Hospital."},{"key":"ref_79","unstructured":"University of Maryland, Baltimore (2022). Phase I Nab-Paclitaxel Plus Gemcitabine with Proton Therapy for Locally Advanced Pancreatic Cancer (LAPC), University of Maryland, Baltimore."},{"key":"ref_80","unstructured":"EBG MedAustron GmbH, and Landesklinkum Wiener Neustadt (2022). Preoperative, Proton- Radiotherapy Combined with Chemotherapy for Borderline Resectable Pancreatic Cancer, Landesklinkum Wiener Neustadt."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1097\/SLA.0000000000005080","article-title":"Local Control and Survival After Induction Chemotherapy and Ablative Radiation Versus Resection for Pancreatic Ductal Adenocarcinoma with Vascular Involvement","volume":"274","author":"Jolissaint","year":"2021","journal-title":"Ann. Surg."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.phro.2021.07.006","article-title":"Feasibility of ablative stereotactic body radiation therapy of pancreas cancer patients on a 1.5 Tesla magnetic resonance-linac system using abdominal compression","volume":"19","author":"Tyagi","year":"2021","journal-title":"Phys. Imaging Radiat. Oncol."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/14\/11\/2789\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T23:24:28Z","timestamp":1760138668000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/14\/11\/2789"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,4]]},"references-count":82,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2022,6]]}},"alternative-id":["cancers14112789"],"URL":"https:\/\/doi.org\/10.3390\/cancers14112789","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,4]]}}}